The effectiveness and value of lecanemab for early Alzheimer disease: A summary from the Institute for Clinical and Economic Review's California Technology Assessment Forum

J Manag Care Spec Pharm. 2023 Sep;29(9):1078-1083. doi: 10.18553/jmcp.2023.29.9.1078.

Authors

Abigail C Wright¹, Grace A Lin¹, Melanie D Whittington¹, Foluso Agboola¹, Serina Herron-Smith¹, David Rind¹, Steven D Pearson¹

Affiliation

¹ Institute for Clinical and Economic Review, Boston, MA.

No abstract available

MeSH terms

Academies and Institutes
Alzheimer Disease* / drug therapy
Cost-Benefit Analysis
Humans
Technology Assessment, Biomedical

Substances

lecanemab